XL 228

Drug Profile

XL 228

Alternative Names: XL-228

Latest Information Update: 09 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Insulin-like growth factor-I receptor antagonists; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Cancer; Chronic myeloid leukaemia

Most Recent Events

  • 22 Feb 2011 XL 228 is available for collaborations or other external opportunities as of 22 Feb 2011. http://www.exelixis.com/
  • 22 Feb 2011 Discontinued - Phase-I for Acute lymphoblastic leukaemia in USA (IV)
  • 22 Feb 2011 Discontinued - Phase-I for Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top